A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.

E Pope, J; Bellamy, N; R Seibold, J; Baron, M; Ellman, M; Carette, S; D Smith, C; M Chalmers, I; Hong, P; O'Hanlon, D; Kaminska, E; Markland, J; Sibley, J; Catoggio, L; E Furst, D

doi:10.1002/1529-0131(200106)44:6<1351::aid-art227>3.0.co;2-i

Public

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.

Published in Arthritis and rheumatism • Jun 1, 2001

NobleIDark:/48914/w1/20260526/B5E4267CRecord on NobleID

Authors:

J E Pope

,

N Bellamy

,

J R Seibold

Abstract

OBJECTIVE: Early diffuse scleroderma (systemic sclerosis; SSc) has no proven treatment. This study was undertaken to examine the efficacy of methotrexate (MTX) in improving the skin and other disease parameters in early diffuse SSc. METHODS: Seventy-one patients with diffuse SSc of <3 years' duratio...

Discussions